Loading data for CLDX — first visit, this takes a few seconds.

알림

Celldex Therapeutics Inc. (CLDX)

NasdaqCM: CLDX · 실시간 가격 · USD

42.23

+0.44 (1.05%)

종가 기준: Aug 18, 2026, 3:59 PM

1.05% (1D)

매수호가	36.43
시가총액	3.28B
매출 (ttm)	158K
순이익 (ttm)	-300.55M
베타	0.84
EPS (ttm)	-4.35
P/E (ttm)	n/a
선행 P/E	-10.04
P/B (ttm)	4.59
P/S (ttm)	20760.62
Earnings Date	Nov 9, 2026

매도호가	48.47
거래량	249,041
평균 거래량 (20일)	1,032,000
시가	42.51
전일 종가	41.79
일중 범위	41.73 - 43.20
52주 범위	20.37 - 45.14
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

CLDX 소개

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that spe...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 May 15, 1986

직원 수 198

상장 거래소 NasdaqCM

티커 CLDX

웹사이트 https://www.celldex.com

전체 기업 정보

재무 실적

2025년 Celldex Therapeutics의 매출은 1.54M로, 전년 7.02M 대비 -77.99% 감소했습니다. 순이익은 -258.76M로, 63.91% 증가했습니다.

재무제표

어닝 서프라이즈

Celldex Therapeutics가 Aug 6, 2026에 분기 실적을 발표했습니다:

매출 $22K 예상치 하회 $0, 및 -96.99% 전년 대비 감소.

EPS -0.94 예상치 상회 0.12, 및 -10.59% 전년 대비 감소.

다음 실적 발표

Celldex Therapeutics Inc.의 실적 발표 예정일은 Nov 9, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · Simply Wall St.

Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results

Celldex Therapeutics (CLDX) released its second quarter 2026 results on 6 August, reporting very limited revenue and a wider net loss. This places the stock’s recent strength in sharper focus for inve...

1주 전 · Simply Wall St.

Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern?

Celldex Therapeutics, Inc. recently reported second-quarter 2026 results, with revenue falling to US$0.022 million and net loss widening to US$73.5 million, while loss per share from continuing operat...

1주 전 · Simply Wall St.

Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return

Celldex Therapeutics stock has more than doubled over the past year, yet its broader valuation checks lean expensive rather than cheap, which raises questions about how much of its pipeline story is a...

1주 전 · Simply Wall St.

What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update?

Celldex Therapeutics (NasdaqCM:CLDX) reported updated clinical pipeline data, including positive Phase 1 results for bispecific antibody CDX-622. The company outlined progress on ongoing Phase 3 studi...

1주 전 · Zacks

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of +9.62% and -98.75%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2 페이지 중 1

Celldex Therapeutics Inc. (CLDX)